Stock Analiz

Arcutis Biotherapeutics, Inc. (ARQT) financials: revenue, earnings and cash flow

Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$16M, a net margin of -4.3%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $509M and net income $30M.

Free cash flow was -$6M in fiscal 2025 and positive in 0 of the 8 years shown.

The diluted share count rose 10163% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2020: $020202021: $020212022: $4M20222023: $60M20232024: $197M20242025: $376M2025$376M
Net income
2018: -$19M20182019: -$42M20192020: -$136M20202021: -$206M20212022: -$311M20222023: -$262M20232024: -$140M20242025: -$16M2025-$16M
Free cash flow
2018: -$14M20182019: -$43M20192020: -$113M20202021: -$176M20212022: -$258M20222023: -$247M20232024: -$112M20242025: -$6M2025-$6M
EPS (diluted)
2018: $-15.5320182019: $-22.7820192020: $-3.8020202021: $-4.1820212022: $-5.6620222023: $-3.7820232024: $-1.1620242025: $-0.132025$-0.13

Income statement

Fiscal yearTTM20252024202320222021202020192018
Revenue$509M$376M$197M$60M$4M$0$0——
Gross profit$464M$339M$177M$55M$3M$0———
Operating income$35M-$12M-$128M-$241M-$302M-$207M-$137M-$43M-$20M
Net income$30M-$16M-$140M-$262M-$311M-$206M-$136M-$42M-$19M
EPS (diluted)$0.21$-0.13$-1.16$-3.78$-5.66$-4.18$-3.80$-22.78$-15.53
R&D$94M$77M$76M$111M$182M$146M$115M$37M$18M
Revenue growth—+91.3%+229.7%+1517.1%—————

Cash flow

Fiscal yearTTM20252024202320222021202020192018
Operating cash flow$60M-$6M-$112M-$247M-$258M-$175M-$113M-$43M-$14M
Capital spending-$255000-$686000-$143000-$428000-$333000-$995000-$321000-$295000$0
Free cash flow$60M-$6M-$112M-$247M-$258M-$176M-$113M-$43M-$14M
Dividends paid—$0$0$0$0$0$0$0$0
Buybacks—————————
Stock-based pay$46M$40M$42M$39M$33M$24M$8M$824000$151000

Balance sheet

Fiscal yearTTM20252024202320222021202020192018
Cash—$221M$228M$272M$410M$387M$284M$101M$39M
Debt—$115M$111M$206M$203M$78M$5M$307000—
Equity—$189M$158M$89M$210M$298M$271M-$65M-$24M
Total assets—$433M$349M$341M$449M$408M$298M$107M—
Shares (diluted)137M127M121M69M55M49M36M2M1M

Margins and returns

Fiscal yearTTM20252024202320222021202020192018
Gross margin91.2%90.2%90.3%91.6%79.5%————
Operating margin6.9%-3.2%-65.3%-404.5%-8183.0%————
Net margin5.9%-4.3%-71.2%-439.8%-8449.8%————
FCF margin11.7%-1.7%-57.1%-415.2%-7000.8%————
ROIC—-3.2%-37.8%-64.7%-57.8%-43.5%-39.2%——
ROE—-8.5%-88.9%-295.7%-148.6%-69.3%-50.1%64.6%80.3%

Frequently asked questions

What is Arcutis Biotherapeutics’s annual revenue?

$376M in fiscal 2025 and $509M over the twelve months to September 30, 2026.

How much profit does Arcutis Biotherapeutics make?

Net income was -$16M in fiscal 2025 (net margin -4.3%).

Is Arcutis Biotherapeutics’s revenue growing?

Yes: revenue rose 91.3% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.